Revelation Biosciences
REVB

$0.8604

0.65%

Market Cap: $3.23M

About: Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

Employees: 9

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

359% more capital invested

Capital invested by funds: $20.9K [Q1] → $95.8K (+$74.9K) [Q2]

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

2.62% more ownership

Funds ownership: 0.47% [Q1] → 3.09% (+2.62%) [Q2]

0% more funds holding

Funds holding: 7 [Q1] → 7 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for REVB.

See Analyst Rankings

Financial journalist opinion

Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds

SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,548,060 shares of common stock, issued by the Company on February 5, 2024 (the “Existing Warrants”), at the reduced e.

Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024

SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, today reported its three and six months ended June 30, 2024 financial results. Corporate Highlights Completed dosing of its first in human phase 1 clinical study of Gem.

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024

How an Election Impacts Penny Stocks

Elections can significantly influence financial markets, including the domain of penny stocks. Penny stocks, often traded below five dollars per share, present a unique opportunity for investors aiming for substantial gains through small initial investments.

How an Election Impacts Penny Stocks

Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity

SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced safety and biomarker data for its Phase 1 clinical study (RVL-HV02). The primary endpoint to evaluate the safety and tolerability of escalating doses of Gemini was met and a maximum tolerated dose in healthy volunteers was identified.

Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity

Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini

SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today that it has completed enrollment and dosing of its first in human Phase 1 clinical study (RVL-HV02). The study, which was conducted in Australia, evaluated escalating doses of intravenously administered Gemini and enrolled 40 healthy.

Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024

SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three months ended March 31, 2024 financial results. Results of Operations As of March 31, 2024, Revelation had $14.6 million in cash and cash equivalents, compared to $12.0 million as of December 31, 2023. The increase in cash and.

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023

SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three and twelve months ended December 31, 2023 financial results. Corporate Highlights Completed a $6.2 million public offering. Commencement of first in human Phase 1 clinical study of Gemini at the beginning of March. Oral prese.

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023

Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)

SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”) a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today new preclinical data on the potential therapeutic benefit of Gemini for the prevention of acute kidney injury (AKI) that was presented at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) taking.

Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)

Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference

SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation) a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today that its Chief Executive Officer James Rolke will participate in a virtual fireside chat at the 36th Annual Roth Conference scheduled for March 17-19, 2023 to be held at The Ritz Carlton, Laguna Niguel in Dana Point, California. Details.

Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference

Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini

SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”) a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today that it has commenced a first in human Phase 1 clinical study (RVL-HV02) to evaluate escalating doses of intravenously administered Gemini. The study is being conducted in Australia and is enrolling healthy individuals 18 to 55 years of.

Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini

See News Rankings